Brind.
  1. Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.

Guardant Health announced a partnership on July 30, 2025, aimed at raising awareness about Colorectal Cancer (CRC) screening.

1 report, 1 independent Updated Jul 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Guardant Health announced a partnership on July 30, 2025, aimed at raising awareness about Colorectal Cancer (CRC) screening.

Who's involved

What this event is mainly about
Guardant Health

Keep exploring

Part of

Guardant Health reported results from Palo Alto on July 31, 2025. Shield MCD received Breakthrough Device Designation from the FDA and was included in NCCN colorectal cancer screening guidelines.

Also in this story

All 3 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireGuardant Health and James Van Der Beek Team Up to Raise Awareness About New Advances in Colorectal Cancer Screening for Adults 45+ 75% of patients who die from colorectal cancer (CRC) are not screene